MX336412B - Nuevos analogos de glucagon. - Google Patents
Nuevos analogos de glucagon.Info
- Publication number
- MX336412B MX336412B MX2012010881A MX2012010881A MX336412B MX 336412 B MX336412 B MX 336412B MX 2012010881 A MX2012010881 A MX 2012010881A MX 2012010881 A MX2012010881 A MX 2012010881A MX 336412 B MX336412 B MX 336412B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- hyperglycemia
- obesity
- diabetes
- glucagon analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
Abstract
La presente invención se refiere a nuevos péptidos de glucagón con solubilidad y estabilidad física mejorada a pH neutral, al uso de estos péptidos en terapia, a métodos de tratamiento que comprende la administración de estos péptidos a pacientes, y al uso de péptidos en la elaboración de medicamentos para el uso en el tratamiento de diabetes, obesidad y condiciones y enfermedades relacionadas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10157901 | 2010-03-26 | ||
US31999410P | 2010-04-01 | 2010-04-01 | |
PCT/EP2011/054714 WO2011117416A1 (en) | 2010-03-26 | 2011-03-28 | Novel glucagon analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012010881A MX2012010881A (es) | 2012-11-06 |
MX336412B true MX336412B (es) | 2016-01-19 |
Family
ID=42710766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012010881A MX336412B (es) | 2010-03-26 | 2011-03-28 | Nuevos analogos de glucagon. |
Country Status (12)
Country | Link |
---|---|
US (8) | US20130035285A1 (es) |
EP (2) | EP2552951A1 (es) |
JP (3) | JP6054861B2 (es) |
KR (1) | KR20130018410A (es) |
CN (2) | CN102918056B (es) |
AU (1) | AU2011231503C1 (es) |
BR (1) | BR112012024379A2 (es) |
CA (1) | CA2792663A1 (es) |
MX (1) | MX336412B (es) |
RU (1) | RU2559320C2 (es) |
WO (2) | WO2011117415A1 (es) |
ZA (1) | ZA201206838B (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013024076A2 (pt) * | 2011-03-28 | 2016-12-06 | Novo Nordisk As | análogos de glucagon |
EP3434687B1 (en) | 2011-06-10 | 2021-03-10 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
CN109306015B (zh) | 2011-06-17 | 2022-04-26 | 韩美科学株式会社 | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 |
TWI596110B (zh) * | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
AR091422A1 (es) | 2012-06-14 | 2015-02-04 | Sanofi Sa | Analogos peptidicos de la exendina 4 |
CA2878991C (en) * | 2012-07-23 | 2021-12-07 | Zealand Pharma A/S | Glucagon analogues |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
CA2890324C (en) | 2012-11-06 | 2021-02-23 | Hanmi Pharm. Co., Ltd. | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
JP6525456B2 (ja) | 2012-11-20 | 2019-06-05 | メデリス ダイアビーティーズ,エルエルシー | インスリン抵抗性のための改善されたペプチド製剤 |
HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
ES2624961T3 (es) | 2013-03-21 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Síntesis de productos de péptido que contienen imida cíclica |
AR095986A1 (es) | 2013-04-03 | 2015-11-25 | Sanofi Sa | Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas |
HUE045573T2 (hu) * | 2013-04-18 | 2020-01-28 | Novo Nordisk As | Stabil, hosszú hatóidejû GLP-1/glükagon receptor ko-agonisták, gyógyászati alkalmazásra |
AU2014255608B2 (en) | 2013-04-18 | 2018-01-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
CA2915922A1 (en) | 2013-06-20 | 2014-12-24 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
US9896495B2 (en) | 2013-10-17 | 2018-02-20 | Zealand Pharma A/S | Acylated glucagon analogues |
KR102310392B1 (ko) * | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-glp-1-gip 삼원 효능제 화합물 |
JP6682432B2 (ja) | 2013-11-06 | 2020-04-15 | ジーランド ファーマ アクティーゼルスカブ | Gip−glp−1デュアルアゴニスト化合物及び方法 |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
AR098616A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
CN106029088A (zh) | 2014-02-18 | 2016-10-12 | 诺和诺德股份有限公司 | 稳定的胰高血糖素类似物以及用于治疗低血糖的用途 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
CN106536547A (zh) * | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
TWI772252B (zh) | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
JP2017536343A (ja) * | 2014-10-10 | 2017-12-07 | ノヴォ ノルディスク アー/エス | 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト |
WO2016066744A2 (en) | 2014-10-29 | 2016-05-06 | Zealand Pharma A/S | Gip agonist compounds and methods |
ES2739289T3 (es) | 2014-11-27 | 2020-01-30 | Novo Nordisk As | Derivados de GLP-1 y sus usos |
CN107108714B (zh) | 2014-12-17 | 2022-02-08 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
US11135271B2 (en) * | 2014-12-30 | 2021-10-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivatives with improved stability |
KR20170137198A (ko) | 2015-04-16 | 2017-12-12 | 질랜드 파마 에이/에스 | 아실화된 글루카곤 유사체 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
EP3322437B1 (en) | 2015-06-30 | 2024-01-17 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
AU2016343775B2 (en) * | 2015-10-28 | 2021-07-29 | Tufts Medical Center | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
BR112018013525A2 (pt) | 2015-12-31 | 2018-12-04 | Hanmi Pharm. Co., Ltd. | conjugado de longa atuação de agonista de receptor de glucagon/glp-1/gip triplo e composição farmacêutica |
SG11201811697SA (en) | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
CN108261391B (zh) * | 2016-12-30 | 2022-03-01 | 江苏太平洋美诺克生物药业有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
CN108261544B (zh) * | 2016-12-30 | 2023-05-05 | 江苏太平洋美诺克生物药业股份有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
KR102665710B1 (ko) | 2017-08-24 | 2024-05-14 | 노보 노르디스크 에이/에스 | Glp-1 조성물 및 그 용도 |
EP3901173A4 (en) | 2018-12-21 | 2022-11-23 | Jiangsu Hengrui Medicine Co., Ltd. | BISPECIFIC PROTEIN |
WO2020163125A1 (en) * | 2019-02-05 | 2020-08-13 | Eli Lilly And Company | Glucagon analog agonists and methods of using the same |
US20220323548A1 (en) * | 2019-08-13 | 2022-10-13 | Anygen Co., Ltd. | Exenatide analog and use thereof |
IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
CN114075275A (zh) * | 2020-08-17 | 2022-02-22 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
MX2023008330A (es) | 2021-01-20 | 2024-01-18 | Viking Therapeutics Inc | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. |
CA3238642A1 (en) * | 2021-11-19 | 2023-05-25 | Zhixiang PAN | Staple-containing polypeptides and application thereof |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA90533B (en) * | 1989-02-01 | 1990-10-31 | Shionogi & Co | A method for the production of glucagon |
US5408037A (en) * | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
WO1997009040A1 (en) | 1995-09-08 | 1997-03-13 | Novo Nordisk A/S | 2-alkylpyrrolidines |
BR9707003A (pt) | 1996-01-17 | 1999-07-20 | Novo Nordisk As | Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto |
WO1997041097A2 (en) | 1996-12-31 | 1997-11-06 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases |
WO1997041120A1 (en) | 1996-07-26 | 1997-11-06 | Dr. Reddy's Research Foundation | Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof |
EP1826216A1 (en) | 1996-08-30 | 2007-08-29 | Novo Nordisk A/S | Glp-1 derivatives |
DE69727837T2 (de) | 1997-05-02 | 2004-12-30 | Dr. Reddy's Research Foundation, Hyderabad | Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
JP2003514508A (ja) | 1997-07-01 | 2003-04-15 | ノボ ノルディスク アクティーゼルスカブ | グルカゴン拮抗剤/逆作用剤 |
CA2294830A1 (en) | 1997-07-16 | 1999-01-28 | John Bondo Hansen | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO1998045292A1 (en) | 1997-12-02 | 1998-10-15 | Dr. Reddy's Research Foundation | Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties |
US6353018B1 (en) | 1998-10-21 | 2002-03-05 | Novo Nordisk A/S | Compounds, their preparation and use |
WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1123292A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1123268A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
WO2000023425A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2002527503A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物類、それらの調製及び使用 |
EP1140945B1 (en) | 1998-12-18 | 2003-06-04 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
WO2000041121A1 (en) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Method and arrangement for issuance and management of digital coupons and sales offers |
WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
AU3033100A (en) | 1999-01-18 | 2000-08-01 | Boehringer Ingelheim International Gmbh | Substituted imidazoles, their preparation and use |
AU2953699A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
WO2000063189A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate |
AU3956900A (en) | 1999-04-16 | 2000-11-02 | Boehringer Ingelheim International Gmbh | Substituted imidazoles, their preparation and use |
EP1171430A1 (en) | 1999-04-16 | 2002-01-16 | Dr. Reddy's Research Foundation | Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them |
WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1171438A1 (en) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Compounds, their preparation and use |
AU3958000A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
JP2002542237A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
WO2000064884A1 (en) | 1999-04-26 | 2000-11-02 | Novo Nordisk A/S | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
AU765753B2 (en) * | 1999-05-17 | 2003-09-25 | Conjuchem Biotechnologies Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
ES2209885T3 (es) * | 1999-05-17 | 2004-07-01 | Conjuchem, Inc. | Peptidos insulinotropicos de larga duracion. |
KR100556323B1 (ko) | 2000-07-20 | 2006-03-03 | 에프. 호프만-라 로슈 아게 | 알파-아실 및 알파-헤테로원자-치환된 벤젠 아세트아미드글루코키나제 활성화제 |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
US7314859B2 (en) | 2002-12-27 | 2008-01-01 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
BR122019021416A2 (es) * | 2003-09-19 | 2019-12-21 | ||
CN101380476A (zh) * | 2003-09-19 | 2009-03-11 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
RU2477286C2 (ru) | 2007-01-05 | 2013-03-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US7994122B2 (en) | 2007-06-15 | 2011-08-09 | Zealand Pharma A/S | Glucagon analogues |
ES2532116T3 (es) | 2007-09-05 | 2015-03-24 | Novo Nordisk A/S | Péptidos derivados con A-B-C-D y sus usos terapéuticos |
US8895694B2 (en) * | 2007-09-05 | 2014-11-25 | Novo Nordisk A/S | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use |
US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
KR101074010B1 (ko) * | 2009-09-04 | 2011-10-17 | (주)이스트소프트 | 블록 단위 데이터 압축 및 복원 방법 및 그 장치 |
-
2011
- 2011-03-28 JP JP2013500534A patent/JP6054861B2/ja not_active Expired - Fee Related
- 2011-03-28 RU RU2012144289/04A patent/RU2559320C2/ru not_active IP Right Cessation
- 2011-03-28 CN CN201180025883.6A patent/CN102918056B/zh not_active Expired - Fee Related
- 2011-03-28 WO PCT/EP2011/054712 patent/WO2011117415A1/en active Application Filing
- 2011-03-28 WO PCT/EP2011/054714 patent/WO2011117416A1/en active Application Filing
- 2011-03-28 AU AU2011231503A patent/AU2011231503C1/en not_active Ceased
- 2011-03-28 CA CA2792663A patent/CA2792663A1/en not_active Withdrawn
- 2011-03-28 CN CN201180025875.1A patent/CN102918055B/zh not_active Expired - Fee Related
- 2011-03-28 KR KR1020127027952A patent/KR20130018410A/ko active Search and Examination
- 2011-03-28 MX MX2012010881A patent/MX336412B/es unknown
- 2011-03-28 BR BR112012024379A patent/BR112012024379A2/pt not_active Application Discontinuation
- 2011-03-28 US US13/637,454 patent/US20130035285A1/en not_active Abandoned
- 2011-03-28 EP EP11710504A patent/EP2552951A1/en not_active Withdrawn
- 2011-03-28 JP JP2013500535A patent/JP6026993B2/ja not_active Expired - Fee Related
- 2011-03-28 EP EP11710218A patent/EP2552950A1/en not_active Withdrawn
- 2011-03-28 US US13/637,522 patent/US20130143798A1/en not_active Abandoned
-
2012
- 2012-09-12 ZA ZA2012/06838A patent/ZA201206838B/en unknown
-
2015
- 2015-06-15 US US14/739,614 patent/US20150274801A1/en not_active Abandoned
- 2015-08-17 US US14/827,539 patent/US20160002311A1/en not_active Abandoned
-
2016
- 2016-05-16 US US15/155,541 patent/US20160271263A1/en not_active Abandoned
- 2016-07-19 JP JP2016141243A patent/JP2016183192A/ja not_active Withdrawn
- 2016-09-12 US US15/262,450 patent/US20170051034A1/en not_active Abandoned
-
2017
- 2017-03-13 US US15/456,912 patent/US20170190757A1/en not_active Abandoned
- 2017-07-26 US US15/660,458 patent/US20180016319A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130143798A1 (en) | 2013-06-06 |
ZA201206838B (en) | 2013-06-26 |
US20170051034A1 (en) | 2017-02-23 |
US20170190757A1 (en) | 2017-07-06 |
US20130035285A1 (en) | 2013-02-07 |
CA2792663A1 (en) | 2011-09-29 |
WO2011117415A1 (en) | 2011-09-29 |
CN102918056A (zh) | 2013-02-06 |
KR20130018410A (ko) | 2013-02-21 |
JP2016183192A (ja) | 2016-10-20 |
RU2012144289A (ru) | 2014-05-10 |
MX2012010881A (es) | 2012-11-06 |
CN102918055B (zh) | 2017-03-29 |
JP2013523619A (ja) | 2013-06-17 |
US20150274801A1 (en) | 2015-10-01 |
AU2011231503B2 (en) | 2014-11-06 |
AU2011231503A1 (en) | 2012-09-27 |
US20180016319A1 (en) | 2018-01-18 |
JP6054861B2 (ja) | 2016-12-27 |
BR112012024379A2 (pt) | 2017-01-10 |
WO2011117416A1 (en) | 2011-09-29 |
US20160271263A1 (en) | 2016-09-22 |
JP6026993B2 (ja) | 2016-11-16 |
AU2011231503C1 (en) | 2016-03-03 |
US20160002311A1 (en) | 2016-01-07 |
CN102918055A (zh) | 2013-02-06 |
CN102918056B (zh) | 2016-08-10 |
RU2559320C2 (ru) | 2015-08-10 |
EP2552951A1 (en) | 2013-02-06 |
EP2552950A1 (en) | 2013-02-06 |
JP2013523618A (ja) | 2013-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX336412B (es) | Nuevos analogos de glucagon. | |
MX2013011175A (es) | Analogos de glucagon novedosos. | |
MY167234A (en) | Novel glucagon analogues | |
MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
EA201201657A1 (ru) | Лечение диабета | |
WO2013186240A3 (en) | Exendin-4 peptide analogues | |
EA201590058A1 (ru) | Аналоги глюкагона | |
WO2008087186A3 (en) | Peptides for use in the treatment of obesity | |
TN2012000249A1 (en) | Pyrazine derivatives and their use in the treatment of neurological disorders | |
WO2008087190A3 (en) | Use of peptides in combination with surgical intervention for the treatment of obesity | |
TW200744642A (en) | Novel peptides for use in the treatment of obesity | |
MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
WO2008087188A3 (en) | Peptides for use in the treatment of obesity | |
PH12019501363A1 (en) | Insulin containing pharmaceutical compositions | |
PH12015501931B1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
MX357071B (es) | Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes. | |
WO2008087189A3 (en) | Peptides for use in the treatment of obesity | |
WO2012092305A3 (en) | Nanonized iron compositions and methods of use thereof | |
PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
NZ702666A (en) | A method of weight reduction | |
UA112981C2 (uk) | Варіант людського gdnf | |
TREBAK | STIM1 and Orai1: novel targets for vascular diseases? | |
MX2016001331A (es) | Compuestos novedosos de indazol y un proceso para preparar los mismos. | |
MD4537C1 (ro) | Soluţie suprasaturată injectabilă de acetaminofen pentru administrare spinală |